Regeneron Follows REGEN-COV Revenue Success With Impressive PD-1 Data
Libtayo Showed Efficacy With Chemo In 1L NSCLC
Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.
